Author: Hermann A.M. Mucke, Ph.D.
FIGURES
Figure 1.1. On- vs. Off-Target Repurposing Contextualized in Three Dimensions: Chemical, Mechanistic, Therapeutic
Figure 2.1. Intellectual Property Protection in On- and Off-Target Repurposing Scenarios
Figure 3.1. Strategies for Repurposing Marketed Drugs vs. Non-Marketed Drug Candidates
Figure 4.1. Regulatory Pathways for Drug Repurposing: Marketed vs. Shelved/Withdrawn Drugs
TABLES
Table 1.1. Use Extensions vs. On- and Off-Target Repurposing
Table 4.1. Regulatory Timelines for a Repurposed Drug vs. a New Chemical Entity (NCE)
Table 5.1. Global Sales (US$ Millions) for Propecia vs. Proscar, 2003–2009
Table 6.1. International PCT Patent Disclosures From Ore Pharmaceuticals
Table 6.2. International PCT Patent Disclosures From Biovista, Inc.
Table 6.3. International PCT Patent Disclosures From Melior Discovery
Table 6.4. International PCT Patent Disclosures From Vifor